BioAtla, Inc. (NASDAQ:BCAB) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET

Company Participants

Bruce Mackle - LifeSci Advisors

Jay Short - Chairman, CEO and Co-Founder

Scott Smith - President

Philippe Martin - Chief of Clinical Development and Operations

Sheri Lydick - SVP, Commercial Strategy

Richard Waldron - CFO

Conference Call Participants

Kelly Shi - Jefferies

Arthur He - H.C. Wainwright

Tony Butler - ROTH Capital

Operator

Hello and welcome to the BioAtla Second Quarter 2022 Earnings Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation there will be an opportunity to ask questions. [Operator Instructions] Please note today's event is being recorded.

I now would like to turn the conference over to your host today, Bruce Mackle. Bruce Mackle, please go ahead.

Bruce Mackle

Thank you, operator, and good afternoon everyone. With me today on the phone from BioAtla are Dr. Jay Short, Chairman, CEO and Co-Founder; Scott Smith, President; Philippe Martin, Chief of Clinical Development and Operations; Sheri Lydick, Senior Vice President, Commercial Strategy; and Richard Waldron, Chief Financial Officer. Earlier this afternoon BioAtla released financial results and a business update for the quarter ended June 30, 2022. A copy of the press release is available on the Company's website.

Before we begin, I'd like to remind everyone that statements made during this conference call will include forward-looking statements including but not limited to statements regarding BioAtla's business plans and prospects, financial and operating performance and expectations, operating costs and expenses, product pipeline, clinical trial and regulatory timing and associated resource requirements, it's programs and potential partnerships and the advancement of its CAB technology and product candidates. These statements are subject to various risks, assumptions and uncertainties that can cause actual results to differ materially and are described in the filings made with the SEC, including the most recent quarterly report on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today, August 9, 2022. And BioAtla disclaims any obligation to update such statements to reflect future information, events or circumstances, except as required by law.

With that, I'd like to turn the call over to Jay Short. Jay?

Jay Short

Thank you, Bruce. Thanks to everyone for joining us for our second quarter 2022 BioAtla earnings call.

The broad applicability of BioAtla's CAB technology has allowed us to continue advancing the development of our innovative clinical and preclinical programs. The second quarter was marked by strong execution with promising results across five potentially registration enabling ongoing Phase 2 trials for our two latest stage CAB-ADC product candidates, Mecbotamab vedotin or BA3011 and Ozuriftabmab vedotin or BA3021 across multiple solid tumor types for these first-in-class therapeutic candidates.